E. Elez

Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer

Background In the phase 3, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pembrolizumab versus chemotherapy provided superior progression-free survival (PFS) at second interim a...

J. Bendell ;

D. Le ;

Takayuki Yoshino , MD, PhD;

W. Zhong ;

T. Andre ;

D. Fogelman ;

K. Shiu ;

P. Marinello ;

T. Kim ;

L. Diaz ;

B. Jensen ;

L. Jensen ;

C. Punt ;

D. Smith ;

Rocio Garcia-Carbonero , MD, PhD;

J. Garcia Alcaide ;

P. Gibbs ;

C. De la Fouchardiere ;

F. Herrero Rivera ;

E. Elez ;

07/02/2021

A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

Background Patients with MSI-H/dMMR mCRC treated with chemotherapy have poorer outcomes than patients with microsatellite stable/MMR proficient mCRC. Pembrolizumab monot...

T. Andre ;

Sara Lonardi ;

S. Abdullaev ;

M. Lei ;

L. Jensen ;

C. De la Fouchardiere ;

E. Elez ;

J. Bennouna ;

G. Mendez ;

J. Li ;

Eric Van Cutsem , MD, PhD;

E. Goekkurt ;

T. Chen ;

Takayuki Yoshino , MD, PhD;

06/27/2022

Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)

Encorafenib plus cetuximab is a standard option in the treatment of BRAFV600E mut mCRC pts pre-treated with at least one systemic therapy. RNF43 is a negative regulator of WNT pathway. A ...

Guglielmo Vetere ;

G. Fontanini ;

Rodrigo De Almeida Toledo ;

F. Bergamo ;

Giovanni Randon , MD;

Simone Oldani ;

Walter Ferrari Bravo ;

Gianmarco Ricagno ;

Paola Vignali ;

Sara Lonardi ;

E. Elez ;

R. Moretto ;